Research protocols typically use 2-2.5mg of TB-500 twice weekly during the acute healing phase, followed by maintenance doses of 2mg once weekly. Dosing should be adjusted based on injury severity and individual response. The peptide is usually administered subcutaneously, though injection site location is flexible due to its systemic effects.
TB-4 dosing research